Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ertapenem + meropenem
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Ertapenem + meropenem is a dual carbapenem antibiotic combination therapy used primarily for treating infections caused by carbapenem-resistant organisms. This combination works through a synergistic mechanism where ertapenem acts as a "suicide substrate" that binds to and saturates carbapenemase enzymes, allowing meropenem to reach its target and exert its bactericidal effect. The combination has shown particular efficacy against infections caused by IMP or NDM-producing organisms with lower minimum inhibitory concentrations.
02
Targets
Beyond the preview
Go deeper on ertapenem + meropenem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ertapenem + meropenem.